Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary.
Angiogenesis is required for normal follicular development but the role of gonadotrophins in the control of follicular angiogenesis remains to be elucidated. This study investigated the effects of treatment with GnRH antagonist in vivo on follicular development and angiogenesis in the marmoset. GnRH antagonist was administered on either follicular day 0 or day 5 of the 10-day follicular phase with ovaries collected on day 10. Ovaries from control marmosets were studied at day 5 (mid follicular phase) and day 10 (periovulatory period). Ovaries were fixed, serial sectioned and subjected to morphological analysis and immunocytochemistry to determine cell proliferation and follicular endothelial cell area and in situ hybridization to assess changes in expression of vascular endothelial growth factor (VEGF). Treatment with GnRH antagonist from day 0-10 resulted in an absence of dominant preovulatory follicles seen in controls. In the remaining tertiary follicles granulosa, theca and endothelial cell proliferation was reduced, resulting in a minor reduction in vascular density. However, VEGF mRNA expression was unaffected by treatment. Treatment from day 5-10 did not prevent development of ovulatory size follicles, but they were atretic and lacked VEGF mRNA. These results suggest that while VEGF expression in the preovulatory follicle is under gonadotrophic control it is not dependent on normal gonadotrophin secretion in tertiary follicles, indicating that there are other paracrine factors regulating VEGF expression in the developing ovarian follicle.
Taylor
P D
PD
Medical Research Council Human Reproductive Sciences Unit, 49 Little France Crescent, Edinburgh EH16 4SB, UK.
Hillier
S G
SG
Fraser
H M
HM
D000818:Animals; D002144:Callithrix; D049109:Cell Proliferation; D048429:Cell Size; D042783:Endothelial Cells / Q000166:cytology; D005260:Female; D005498:Follicular Phase; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006727:Hormone Antagonists / Q000494:pharmacology*; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization / Q000379:methods; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009842:Oligopeptides / Q000494:pharmacology*; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010053:Ovary / Q000098:blood supply / Q000166:cytology; D012333:RNA, Messenger / Q000032:analysis; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics
D006727:Hormone Antagonists; D009842:Oligopeptides; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D007987:Gonadotropin-Releasing Hormone; C084350:antarelix